Biomarkers of phenethyl isothiocyanate-mediated mammary cancer chemoprevention in a clinically relevant mouse model

Journal of the National Cancer Institute

Volumn 104, Issue 16, 2012, Pages 1228-1239

  Singh, Shivendra V ^a,d   Kim, Su Hyeong ^a   Sehrawat, Anuradha ^a   Arlotti, Julie A ^d   Hahm, Eun Ryeong ^a   Sakao, Kozue ^a   Beumer, Jan H ^d,e   Jankowitz, Rachel C ^b,d   Chandra Kuntal, Kumar ^a   Lee, Joomin ^a   Powolny, Anna A ^a   Dhir, Rajiv ^c,d  

^a Department of Medicine ^*  (United States)

^b Division of Hematology and Oncology   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD31 ANTIGEN; EOSIN; HEMATOXYLIN; PHENETHYL ISOTHIOCYANATE; PREALBUMIN; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST; BREAST CANCER; CANCER INCIDENCE; CANCER INHIBITION; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DIET SUPPLEMENTATION; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETER; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS; TISSUE SECTION; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTIGENS, CD31; APOPTOSIS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; GENE EXPRESSION PROFILING; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; ISOTHIOCYANATES; KI-67 ANTIGEN; MAMMARY NEOPLASMS, EXPERIMENTAL; MAMMARY TUMOR VIRUS, MOUSE; MASS SPECTROMETRY; MICE; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; PREALBUMIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84865513369     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs321     Document Type: Article

References (38)

1. Hulka BS, Stark AT. Breast cancer: cause and prevention. Lancet. 1995;346(8979):883-887.
2. Zhang Y, Kiel DP, Kreger BE, et al. Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med. 1997;336(9):611-617. (Pubitemid 27093406)
3. van Zitteren M, van der Net JB, Kundu S, Freedman AN, van Duijn CM, Janssens AC. Genome-based prediction of breast cancer risk in the general population: a modeling study based on meta-analyses of genetic associations. Cancer Epidemiol Biomarkers Prev. 2011;20(1):9-22.
4. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
5. Alvarez RH. Present and future evolution of advanced breast cancer therapy. Breast Cancer Res. 2010;12(suppl 2):S1.
6. Higgins MJ, Baselga J. Breast cancer in 2010: novel targets and therapies for a personalized approach. Nat Rev Clin Oncol. 2011;8(2):65-66.
7. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 1998;90(18):1371-1388. (Pubitemid 28439961)
8. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat. 2001;65(2):125-134. (Pubitemid 32193616)
9. Goss PE, Ingle JN, Alés-Martínez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364(25):2381-2391.
10. Obiorah I, Jordan VC. Progress in endocrine approaches to the treatment and prevention of breast cancer. Maturitas. 2011;70(4):315-321.
11. Boccardo F, Rubagotti A, Guglielmini P, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol. 2006;17(suppl 7):vii,10-14.
12. Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer. 2003;3(10):768-780.
13. Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod. 2003;66(7):1022-1037. (Pubitemid 36909859)
14. Fahey JW, Zalcmann AT, Talalay P. The chemical diversity and distribution of glucosinolates and isothiocyanates among plants. Phytochemistry. 2001;56(1):5-51. (Pubitemid 32063165)
15. Hecht SS. Inhibition of carcinogenesis by isothiocyanates. Drug Metab Rev. 2000;32(3-4):395-411. (Pubitemid 32001915)
16. Wattenberg LW. Inhibition of carcinogenic effects of polycyclic hydrocarbons by benzyl isothiocyanate and related compounds. J Natl Cancer Inst. 1977;58(2):395-398. (Pubitemid 8042532)
17. Stoner GD, Morrissey DT, Heur YH, Daniel EM, Galati AJ, Wagner SA. Inhibitory effects of phenethyl isothiocyanate on N-nitrosobenzylmethylamine carcinogenesis in the rat esophagus. Cancer Res. 1991;51(8):2063-2068.
18. Khor TO, Cheung WK, Prawan A, Reddy BS, Kong AN. Chemoprevention of familial adenomatous polyposis in ApcMin/+ mice by phenethyl isothiocyanate (PEITC). Mol Carcinog. 2008;47(5):321-325. (Pubitemid 351614572)
19. Powolny AA, Bommareddy A, Hahm ER, et al. Chemopreventative potential of the cruciferous vegetable constituent phenethyl isothiocyanate in a mouse model of prostate cancer. J Natl Cancer Inst. 2011;103(7):571-584.
20. Xiao D, Powolny AA, Moura MB, et al. Phenethyl isothiocyanate inhibits oxidative phosphorylation to trigger reactive oxygen species-mediated death of human prostate cancer cells. J Biol Chem. 2010;285(34):26558-26569.
21. Hahm ER, Singh SV. Bim contributes to phenethyl isothiocyanate-induced apoptosis in breast cancer cells. Mol Carcinog. 2012;51(6):465-474.
22. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177-182. (Pubitemid 17231334)
23. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA. 1992;89(22):10578-10582.
24. Ménard S, Tagliabue E, Campiglio M, Pupa SM. Role of HER2 gene overexpression in breast carcinoma. J Cell Physiol. 2000;182(2):150-162. (Pubitemid 30022667)
25. Warin R, Chambers WH, Potter DM, Singh SV. Prevention of mammary carcinogenesis in MMTV-neu mice by cruciferous vegetable constituent benzyl isothiocyanate. Cancer Res. 2009;69(24):9473-9480.
26. Xiao D, Singh SV. Phenethyl isothiocyanate inhibits angiogenesis in vitro and ex vivo. Cancer Res. 2007;67(5):2239-2246. (Pubitemid 46424243)
27. Folkman J. Tumor angiogenesis: therapeutic implications. N Eng J Med. 1971;285(21):1182-1186.
28. Powolny AA, Bommareddy A, Singh SV. Slow but steady progress in cancer chemoprevention with phenethyl isothiocyanate: fulfilled promises and translational challenges. In: Sarkar FH, ed. Neutraceuticals and Cancer. Houten, Netherlands: Springer Science+Business Media B.V.; 2012:231-258.
29. Mi L, Hood BL, Stewart NA, et al. Identification of potential protein targets of isothiocyanates by proteomics. Chem Res Toxicol. 2011;24(10):1735- 1743.
30. Huang TC, Chang HY, Hsu CH, Kuo WH, Chang KJ, Juan HF. Targeting therapy for breast carcinoma by ATP synthase inhibitor aurovertin B. J Proteome Res. 2008;7(4):1433-1444.
31. Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol. 2005;15(4):300-308. (Pubitemid 41058775)
32. Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell. 2006;9(6):425-434. (Pubitemid 43832190)
33. Huang P, Liu J, Di A, et al. Regulation of human CLC-3 channels by multifunctional Ca2 +calmodulin-dependent protein kinase. J Biol Chem. 2001;276(23):20093-20100.
34. Zimmermann U, Balabanov S, Giebel J, et al. Increased expression and altered location of annexin IV in renal clear cell carcinoma: a possible role in tumour dissemination. Cancer Lett. 2004;209(1):111-118. (Pubitemid 38625750)
35. Han EK, Tahir SK, Cherian SP, Collins N, Ng SC. Modulation of paclitaxel resistance by annexin IV in human cancer cell lines. Br J Cancer. 2000;83(1):83-88. (Pubitemid 30352721)
36. Shenkin A. Serum prealbumin: is it a marker of nutritional status or of risk of malnutrition? Clin Chem. 2006;52(12):2177-2179. (Pubitemid 44924987)
37. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340(6):448-454. (Pubitemid 29084777)
38. Brauer HA, Libby TE, Mitchell BL, et al. Cruciferous vegetable supplementation in a controlled diet study alters the serum peptidome in a GSTM1-genotype dependent manner. Nutr J. 2011;10:11.